Results 11 to 20 of about 70 (42)

Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet

open access: yesNefrología (English Edition), 2023
Introduction: There is scarce clinical experience with etelcalcetide in patients with secondary hyperparathyroidism uncontrolled with cinacalcet. The effect of etelcalcetide on serum sclerostin levels remains to be clarified.
Luciano Artur Lopes Pereira   +6 more
doaj   +3 more sources

Serum sclerostin in acute kidney injury patients

open access: yesNefrología (English Edition), 2022
Background: Many of the mineral metabolite abnormalities encountered in chronic kidney disease (CKD) patients were found also associated with acute kidney injury (AKI). In the last decade, sclerostin was found to intimately affect bone mineral metabolism
Ahmed Fayed   +8 more
doaj   +1 more source

The correlation between sclerostin and bone mineral density in renal transplant recipients

open access: yesNefrología (English Edition), 2020
Introduction: Sclerostin is an anti-anabolic protein synthesized by osteocytes that may cause osteoporosis by inhibiting bone formation. The aim of our study was to investigate the correlation between sclerostin and bone mineral density (BMD) reduction ...
Melahat Coban, Sarper Okten
doaj   +3 more sources

Búsqueda de variantes del gen LRP4 en mujeres con alta masa ósea y en pacientes con malformación de Chiari tipo I

open access: yesRevista de Osteoporosis y Metabolismo Mineral, 2021
Objetivo: LRP4 es un facilitador esencial en la inhibición específica de esclerostina de la vía canónica de Wnt. Mutaciones en LRP4 se han asociado a diversas patologías entre las cuales se incluyen la patología de crecimiento óseo, esclerosteosis y la ...
Martínez-Gil N, Grinberg D, Balcells S
doaj   +1 more source

Papel del Romosozumab en la práctica clínica a la luz de la evidencia

open access: yesRevista Colombiana de Endocrinología, Diabetes y Metabolismo, 2022
La osteoporosis es una enfermedad sistémica ósea caracterizada por un deterioro en la calidad y cantidad de hueso que determina un riesgo de fracturas. Existen múltiples opciones de tratamiento para disminuir este desenlace.
Alejandro Román-González   +2 more
doaj   +1 more source

Vías de señalización anabólicas en el hueso y su potencial aplicación en la terapéutica

open access: yesRevista Colombiana de Endocrinología, Diabetes y Metabolismo, 2017
Para el manejo actual de la osteoporosis contamos con la terapia antirresortiva, que estabiliza la arquitectura ósea sin lograr su restauración y la anabólica (teriparatida: único aprobado por la FDA) que restaura y aumenta la masa ósea.
Ariana Sierra   +5 more
doaj   +1 more source

Medicamentos para o tratamento da osteoporose: revisão Drugs for the management of osteoporosis: a review

open access: yesRevista Brasileira de Reumatologia, 2011
A osteoporose caracteriza-se por reduzida massa óssea e deterioração microarquitetural do tecido ósseo, o que aumenta a fragilidade óssea e, portanto, a suscetibilidade a fraturas.
Deepak Kumar Khajuria   +2 more
doaj   +1 more source

Vascular calcification in peritoneal dialysis patients and its association with bone-derived molecules and bone histomorphometry

open access: yesNefrología (English Edition)
Introduction: Data regarding vascular calcification (VC) in contemporary peritoneal dialysis (PD) patients is scarce. Bone–vascular axis has been demonstrated in hemodialysis (HD).
Luciano Pereira   +7 more
doaj   +3 more sources

Home - About - Disclaimer - Privacy